KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $205.1 million.

  • Sarepta Therapeutics' Share-based Compensation fell 66.54% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year decrease of 18.31%. This contributed to the annual value of $205.1 million for FY2024, which is 12.39% up from last year.
  • Sarepta Therapeutics' Share-based Compensation amounted to $205.1 million in FY2024, which was up 12.39% from $182.5 million recorded in FY2023.
  • Sarepta Therapeutics' Share-based Compensation's 5-year high stood at $233.0 million during FY2022, with a 5-year trough of $108.1 million in FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $205.1 million (2024), whereas its average is $206.9 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Share-based Compensation skyrocketed by 104.50% in 2022 and then fell by 21.67% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Share-based Compensation (Yearly) stood at $108.1 million in 2020, then climbed by 5.43% to $113.9 million in 2021, then surged by 104.50% to $233.0 million in 2022, then decreased by 21.67% to $182.5 million in 2023, then rose by 12.39% to $205.1 million in 2024.